The uremic syndrome is a complex mixture of organ dysfunctions, which is attributed to the retention of a myriad of compounds that under normal condition are excreted by the healthy kidneys (uremic toxins). In the area of identification and characterization of uremic toxins and in the knowledge of their pathophysiologic importance, major steps forward have been made during recent years. The present article is a review of several of these steps, especially in the area of information about the compounds that could play a role in the development of cardiovascular complications. It is written by those members of the Uremic Toxins Group, which has been created by the European Society for Artificial Organs (ESAO). Each of the 16 authors has written a state of the art in his/her major area of interest.
LesafferG., De SmetR., LameireN.. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.Nephrol Dial Transplant2000; 15: 50–7.
2.
AbreoK., SellaM., GautreauxS.. P-Cresol, a uremic compound, enhances the uptake of aluminum in hepatocytes.J Am Soc Nephrol1997; 8: 935–42.
3.
VanholderR., De SmetR.. Pathophysiologic effects of uremic retention solutes.J Am Soc Nephrol1999; 10: 1815–23.
4.
Witko-SarsatV., Descamps-LatschaB.. Advanced oxidation protein products: novel uraemic toxins and proinflammatory mediators in chronic renal failure?Nephrol Dial Transplant1997; 12: 1310–12.
5.
VlassaraH.. Serum advanced glycosylation end products: a new class of uremic toxins?Blood Purif1994; 12: 54–9.
6.
DhondtA., VanholderR., Van BiesenW., LameireN.. The removal of uremic toxins.Kidney Int2000; 58(suppl 76): S47–59.
7.
MakitaZ.. Toxicity of glucose: is AGE the answer?.Nephrol Dial Transplant1995; 10(suppl 7): S33–7.
8.
NiwaT.. Mass spectrometry in the search for uremic toxins.Mass Spectrom Rev1997; 16: 307–32.
9.
NorisM., BenigniA., BoccardoP.. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension.Kidney Int1993; 44: 445–50.
VanholderR., Van LooA., DhondtAM. Second symposium on uraemic toxicity. Summary of a symposium held in Gent, Belgium, 22-24 September 1994.Nephrol Dial Transplant1995; 10: 414–18.
12.
VanholderR., De SmetR., HsuC., VogeleereP., RingoirS.. Uremic toxicity: the middle molecule hypothesis revisited.Semln Nephrol1994; 14: 205–18.
13.
StenvinkelP., HeimburgerO., PaultreF.. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.Kidney Int1999; 55: 1899–911.
14.
RajD.S., ChoudhuryD., WelbourneT.C., LeviM.. Advanced glycation end products: a nephrologist's perspective.Am J Kidney Dis2000; 35: 365–80.
15.
WrattenM.L., TettaC., UrsiniF., SevanianA.. Oxidant stress in hemodialysis: prevention and treatment strategies.Kidney Int2000; 58(suppl 76): S126–32.
16.
GejyoF., YamadaT., OdaniS.. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin.Biochem Biophys Res Commun1985; 129: 701–6.
17.
SharmaK., ConsidineR.V., MichaelB.. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients.Kidney Int1997; 51: 1980–5.
18.
HorlW.H., Haag-WeberM., GeorgopoulosA., BlockL.H.. Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells.Proc Natl Acad Sci USA1990; 87: 6353–7.
19.
CohenG., RudnickiM., HorlW.H.. Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients.J Am Soc Nephrol1998; 9: 451–6.
20.
MakitaZ., BucalaR., RayfieldE.J.. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.Lancet1994; 343: 1519–22.
21.
IshimitsuT., NishikimiT., SaitoY.. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure.J Clin Invest1994; 94: 2158–61.
22.
PascualM., SteigerG., EstreicherJ.. Metabolism of complement factor D in renal failure.Kidney Int1988; 34: 529–36.
23.
AssenatH., CalemardE., CharraB.. Héemodialyse, syndrome du canal canal et substance amyloïde.Nouv Presse Med1980; 9: 1715.
24.
HerveJ.P., CledesJ., BourbigotB.. Systemic amyloidosis in the course of maintenance hemodialysis.Nephron1985; 40: 494.
25.
OgawaH., SaitoA., HirabayashiN., HaraK.. Amyloid deposition in systemic organs in long-term hemodialysis patients.Clin Nephrol1987; 28: 199–204.
26.
OlietA., AndresA., PragaM.. Systemic amyloidosis in a chronic hemodialysis patient.Am J Nephrol1987; 7: 162–3.
MaruyamaH., GejyoF., ArakawaM.. Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients.Nephron1992; 61: 37–44.
31.
OhashiK., HaraM., KawaiR.. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column.Kidney Int1992; 41: 1646–52.
32.
AllainT.J., StevensP.E., BridgesL.R., PhillipsM.E.. Dialysis myelopathy: quadriparesis due to extradural amyloid of beta 2 microglobulin origin.BMJ1988; 296: 752–3.
33.
SanchezR., PragaM., Rivas SalasJ.J.. Compressive myelopathy due to dialysis-associated amyloidosis.Nephron1993; 65: 463–5.
34.
DaneshF.R., KlinkmannJ., YokooH., IvanovichP.. Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of beta2-microglobulin amyloid.Am J Kidney Dis1999; 33: 563–6.
DiRaimondoC.R., CaseyT.T., DiRaimondoC.V., StoneW.J.. Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients.Nephron1986; 43: 22–7.
37.
BrancaccioD., GallieniM., PadoveseP.. Dialysis amyloidosis with massive popliteal deposition of beta 2-microglobulin amyloid.Lancet1988; 2: 802.
38.
CampistolJ.M., ArgilesA.. Dialysis-related amyloidosis: visceral involvement and protein constituents.Nephrol Dial Transplant1996; 11(suppl 3): 142–5.
39.
LinkeR.P., BommerJ., RitzE., WaldherrR., EulitzM.. Amyloid kidney stones of uremic patients consist of beta 2-microglobulin fragments.Biochem Biophys Res Commun1986; 136: 665–71.
40.
WatanabeK., NakamuraR., KanoS.. Amyloid urinary-tract calculi in patients on chronic dialysis.Nephron1989; 52: 334–7.
41.
CharraB., CalemardE., LaurentG.. Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome.Blood Purif1988; 6: 117–24.
42.
SchwalbeS., HolzhauerM., SchaefferJ.. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis?Kidney Int1997; 52: 1077–83.
GejyoF., HommaN., SuzukiY., ArakawaM.. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis.N Engl J Med1986; 314: 585–6.
45.
WalzG., KunzendorfU., SchwarzA.. Elevated tissue polypeptide antigen as a risk factor for carpal tunnel syndrome in haemodialyzed patients.Nephron1988; 50: 83–4.
46.
HurstN.P., van denB.R., DisneyA.. Dialysis related arthropathy: a survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis.Ann Rheum Dis1989; 48: 409–20.
47.
RoncoC., HeifetzA., FoxK.. Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule.Int J Artif Organs1997; 20: 136–43.
48.
MouradG., ArgilesA.. Renal transplantation relieves the symptoms but does not reverse beta 2- microglobulin amyloidosis.J Am Soc Nephrol1996; 7: 798–804.
49.
van YperseledS, JadoulM., MalghemJ., MaldagueB., JamartJ.. Effect of dialysis membrane and patient's age on signs of dialysis- related amyloidosis. The Working Party on Dialysis Amyloidosis.Kidney Int1991; 39: 1012–19.
50.
AoyagiR., MiuraY., IshiyamaT., MaruyamaY., HasegawaH.. Influence of dialysis membranes on the development of dialysis associated osteoarthropathy.Kidney Int1993; 43(suppl 41): S111–5.
51.
HakimR.M.. Clinical implications of hemodialysis membrane biocompatibility.Kidney Int1993; 44: 484–94.
52.
ChanardJ., BindiP., LavaudS.. Carpal tunnel syndrome and type of dialysis membrane.BMJ1989; 298: 867–8.
53.
BonominiV., ColiL., FeliciangeliG., NanniC.A., ScolariM.P.. Long-term comparative evaluation of synthetic and cellulosic membranes in dialysis.Int J Artif Organs1994; 17: 392–8.
54.
KesslerM., NetterP., MaheutH.. Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy.Lancet1991; 337: 1092–3.
55.
LinkeR.P., HamplH., Bartel-SchwarzeS., EulitzM.. Beta 2-microglobulin, different fragments and polymers thereof in synovial amyloid in long-term hemodialysis.Biol Chem Hoppe Seyler1987; 368: 137–44.
56.
LinkeR.P., HamplH., LobeckH.. Lysine-specific cleavage of beta 2-microglobulin in amyloid deposits associated with hemodialysis.Kidney Int1989; 36: 675–81.
57.
OdaniH., OyamaR., TitaniK., OgawaH., SaitoA.. Purification and complete amino acid sequence of novel beta 2-microglobulin.Biochem Biophys Res Commun1990; 168: 1223–9.
58.
OgawaH., SaitoA., OdaO., NakajimaM., ChungT.G.. Detection of novel beta 2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition.Clin Nephrol1988; 30: 158–63.
59.
MiyataT., OdaO., InagiR V.. Beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.J Clin Invest1993; 92: 1243–52.
60.
GorevicP.D., MunozP.C., CaseyT.T.. Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis.Proc Natl Acad Sci USA1986; 83: 7908–12.
61.
ArgilesA., MouradG., Axelrud-CavadoreC.. Haemodialysis-associated amyloidosis: beta 2-microglobulin alone or associated with globin chains?Clin Sei1987; 73: 515–8.
62.
ArgilesA., Garcia-GarciaM., DerancourtJ., MouradG., DemailleJ.G.. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits.Kidney Int1995; 48: 1397–405.
63.
CampistolJ.M., BernardD., PapastoitsisG.. Polymerization of normal and intact beta 2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis.Kidney Int1996; 50: 1262–7.
64.
ArgilesA., DerancourtJ., Jauregui-AdellJ., MionC., DemailleJ.G.. Biochemical characterization of serum and urinary beta 2 microglobulin in end-stage renal disease patients.Nephrol Dial Transplant1992; 7: 1106–10.
65.
ArgilesA., Gouin-CharnetA., WuY.C., MouradG., FriedlanderM.A.. Elevated pentosidine content in amyloid deposits and in insoluble amyloid fibrils from patients with beta 2-microglobulin amyloidosis.Nephrol Dial Transplant1996; 11: 2371–2.
66.
ArgilesA., MouradG., Gouin-CharnetA., Schmitt-BernardC.F.. Antiproteases and cells in the pathogenesis of beta(2)-microglobulin amyloidosis: role of alpha(2)-macroglobulin and macrophages.Nephron2000; 86: 1–11.
67.
SnowA.D., WillmerJ., KisilevskyR.. Sulfated glycosa-minoglycans: a common constituent of all amyloids?Lab Invest1987; 56: 120–3.
68.
OhishiH., SkinnerM., Sato-ArakiN.. Glycosa-minoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen.Clin Chem1990; 36: 88–91.
69.
ArugaE., OzasaH., TeraokaS., OtaK.. Macromolecules that are colocalized with deposits of beta 2- microglobulin in hemodialysis-associated amyloidosis.Lab Invest1993; 69: 223–30.
70.
AthanasouN.A., PuddleB., SallieB.. Highly sulphated glycosaminoglycans in articular cartilage and other tissues containing beta 2 microglobulin dialysis amyloid deposits.Nephrol Dial Transplant1995; 10: 1672–8.
71.
HoickM., HusbyG., SlettenK., NatvigJ.B.. The amyloid P-component (protein AP): an integral part of the amyloid substance?Scand J Immunol1979; 10: 55–60.
72.
PepysM.B.. Amyloidosis: some recent developments.Q J Med1988; 67: 283–98.
73.
CoriaF., CastanoE., PrelliF.. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis.Lab Invest1988; 58: 454–8.
74.
DepierreuxM., GoldmanM., FaytI.. Osteoarticular amyloidosis associated with haemodialysis: an immunoultrastructural study.J Clin Pathol1988; 41: 158–62.
75.
Garcia-GarciaM., ArgilesA., Gouin-CharnetA.. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis.Kidney Int1999; 55: 899–906.
76.
GarbarC., JadoulM., NoelH., van Ypersele de StrihouC.. Histological characteristics of sternoclavicular beta 2-microglobulin amyloidosis and clues for its histogenesis.Kidney Int1999; 55: 1983–90.
77.
HeimburgerO., LonnqvistF., DanielssonA., NordenstromJ., StenvinkelP.. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure.J Am Soc Nephrol1997; 8: 1423–30.
YoungG.A., WoodrowG., KendallS.. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition?Nephrol Dial Transplant1997; 12: 2318–23.
80.
WidjajaA., KielsteinJ.T., HornR.. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease.Nephrol Dial Transplant2000; 15: 846–50.
81.
StenvinkelP., LonnqvistF., SchallingM.. Molecular studies of leptin: implications for renal disease.Nephrol Dial Transplant1999; 14: 1103–12.
82.
DucyP., AmlingM., TakedaS.. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass.Cell2000; 100: 197–207.
83.
NordforsL., LonnqvistF., HeimburgerO.. Low leptin gene expression and hyperleptinemia in chronic renal failure.Kidney Int1998; 54: 1267–75.
84.
CuminF., BaumH.P., LevensN.. Leptin is cleared from the circulation primarily by the kidney.Int J Obes Relat Metab Disord1996; 20: 1120–6.
85.
ZengJ., PattersonB.W., KleinS.. Whole body leptin kinetics and renal metabolism in vivo.Am J Physiol1997; 273: E1102–E1106.
86.
KokotF., AdamczakM., WiecekA.. Plasma leptin concentration in kidney transplant patients during the early post-transplant period.Nephrol Dial Transplant1998; 13: 2276–80.
87.
StenvinkelP., HeimburgerO., LonnqvistF.. Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure.Nephrol Dial Transplant1997; 12: 1321–5.
88.
FouqueD., JuillardL., LasneY.. Acute leptin regulation in end-stage renal failure: the role of growth hormone and IGF-1.Kidney Int1998; 54: 932–7.
89.
GaribottoG., RussoR., FranceschiniR.. Inter-organ leptin exchange in humans.Biochem Biophys Res Commun1998; 247: 504–9.
90.
GrunfeldC., ZhaoC., FullerJ.. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters.J Clin Invest1996; 97: 2152–7.
91.
SarrafP., FrederichR.C., TurnerE.M.. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.J Exp Med1997; 185: 171–5.
DonB.R., RosalesL.M., LevineN.W., MitchW., KaysenG.A.. Leptin is a negative acute phase protein in chronic hemodialysis patients.Kidney Int2001; 59: 1114–20.
95.
DaschnerM., TonshoffB., BlumW.. Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.J Am Soc Nephrol1998; 9: 1074–9.
96.
JohansenK.L., MulliganK., TaiV., SchambelanM.. Leptin, body composition, and indices of malnutrition in patients on dialysis.J Am Soc Nephrol1998; 9: 1080–4.
97.
OdamakiM., FuruyaR., YoneyamaT.. Association of the serum leptin concentration with weight loss in chronic hemodialysis patients.Am J Kidney Dis1999; 33: 361–8.
98.
StenvinkelP., LindholmB., LonnqvistF., KatzarskiK., HeimburgerO.. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass.J Am Soc Nephrol2000; 11: 1303–9.
Haag-WeberM., MaiB., HorlW.H.. Isolation of a granulocyte inhibitory protein from uraemic patients with homology of beta 2-microglobulin.Nephrol Dial Transplant1994; 9: 382–8.
101.
TschescheH., KoppC., HorlW.H., HempelmannU.. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment.J Biol Chem1994; 269: 30274–80.
102.
BalkeN., HoltkampU., HorlW.H., TschescheH.. Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D.FEBS Lett1995; 371: 300–2.
103.
Hannam-HarrisA.C., GordonJ., SmithJ.L.. Immunoglobulin synthesis by neoplastic B lymphocytes: free light chain synthesis as a marker of B cell differentiation.J Immunol1980; 125: 2177–81.
WakasugiK., SasakiM., SuzukiM., AzumaN., NobutoT.. Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients.Biomater Artif Cells Immobilization Biotechnol1991; 19: 97–109.
106.
CohenG., Haag-WeberM., MaiB., DeicherR., HorlW.H.. Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions.J Am Soc Nephrol1995; 6: 1592–9.
107.
CohenG., HorlW.H.. Free immunoglobulin light chains contribute to the pre-stimulation of neutrophils in uremia.(Abstract) Kidney Blood Press Res2000; 23: 261.
108.
CohenG., RudnickiM., HorlW.H.. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils.Kidney Int2001; 59: 48–52.
109.
Descamps-LatschaB.. The immune system in end-stage renal disease.Curr Opin Nephrol Hypertens1993; 2: 883–91.
110.
LedlF., SchleicherE.. New aspects of the Maillard reaction in food and in the human body.Angew Chem Int Ed Engl1990; 29: 565–94.
111.
ThorpeS.R., BaynesJ.W.. Role of the Maillard reaction in diabetes mellitus and diseases of aging.Drugs Aging1996; 9: 69–77.
MakitaZ., RadoffS., RayfieldE.J.. Advanced glycosylation end products in patients with diabetic nephropathy.N Engl J Med1991; 325: 836–42.
114.
MiyataT., OdaO., InagiR.. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.J Clin Invest1993; 92: 1243–52.
115.
VlassaraH., StrikerL.J., TeichbergS.. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.Proc Natl Acad Sci USA1994; 91: 11704–8.
116.
SakataN., ImanagaY., MengJ.. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease.Atherosclerosis1999; 142: 67–77.
117.
FishbaneS., BucalaR., PereiraB.J., FoundsH., VlassaraH.. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.Kidney Int1997; 52: 1645–50.
118.
NakayamaM., KawaguchiY., YamadaK.. Immuno-histochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51: 182–6.
119.
MiyataT., lidaY., UedaY.. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.Kidney Int1996; 49: 538–50.
120.
ThornalleyP.J.. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs.Cell Mol Biol1998; 44: 1013–23.
121.
MiyataT., WadaY., CaiZ.. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.Kidney Int1997; 51: 1170–81.
122.
DevuystO., van Ypersele de StrihouC.. Nitric oxide, advanced glycation end products, and uremia.Kidney Int2000; 58: 1814–5.
123.
AsahiK., IchimoriK., NakazawaH.. Nitric oxide inhibits the formation of advanced glycation end products.Kidney Int2000; 58: 1780–7.
124.
VerbekeP., PerichonM., FriguetB., BakalaH.. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells.Biochim BiophysActa2000; 1502: 481–94.
125.
CohenG., RudnickiM., WalterF., NiwaT., HorlW.H.. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes.J Am Soc Nephrol2001; 12: 1264–71.
126.
RitzE., DeppischR., NawrothP.. Toxicity of uraemia - does it come of AGE?Nephrol Dial Transplant1994; 9: 1–2.
HenleT., DeppischR., BeckW.. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.Nephrol Dial Transplant1999; 14: 1968–75.
129.
OdaniH., ShinzatoT., UsamiJ.. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: evidence for increased oxidative stress in uremia.FEBS Lett1998; 427: 381–5.
130.
OdaniH., ShinzatoT., MatsumotoY.. First evidence for accumulation of protein-bound and protein-free pyrraline in human uremic plasma by mass spectrometry.Biochem Biophys Res Commun1996; 224: 237–41.
131.
AhmedM.U., ThorpeS.R., BaynesJ.W.. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein.J Biol Chem1986; 261: 4889–94.
132.
KumeS., TakeyaM., MoriT.. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.Am J Pathol1995; 147: 654–67.
133.
StittA.W., HeC., FriedmanS.. Elevated AGE-modified ApoB in sera of euglycemic, normollpidemic patients with atherosclerosis: relationship to tissue AGEs.Mol Med1997; 3: 617–27.
134.
NakamuraY., HoriiY., NishinoT.. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus.Am J Pathol1993; 143: 1649–56.
135.
HenleT., DeppischR., RitzE.. The Maillard reaction-from food chemistry to uraemia research.Nephrol Dial Transplant1996; 11: 1718–22.
136.
OimomiM., NishimotoS., KitamuraY.. Increased fructose-lysine of hair protein in diabetic patients.Klin Wochenschr1985; 63: 728–30.
137.
Portero-OtinM., NagarajR.H., MonnierV.M.. Chromatographic evidence for pyrraline formation during protein glycation in vitro and in vivo.Biochim BiophysActa1995; 1247: 74–80.
138.
SellD.R., MonnierV.M.. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process.J Biol Chem1989; 264: 21597–602.
139.
GlombM.A., MonnierV.M.. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction.J Biol Chem1995; 270: 10017–26.
140.
LedlF., OsianderH., PachmayrO., SeverinT.. Formation of maltosine, a product of the Maillard reaction with a pyridone structure.Z Lebensm Unters Forsch1989; 188: 207–11.
141.
WestwoodM.E., ThornalleyP.J.. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins.J Protein Chem1995; 14: 359–72.
142.
SchwarzenbolzU., HenleT., HaessnerR., KlostermeyerH.. On the reaction of glyoxal with proteins.Z Lebensm Unters Forsch1997; 205: 121–4.
143.
ShipanovaI.N., GlombM.A., NagarajR.H.. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct.Arch Biochem Biophys1997; 344: 29–36.
144.
ObayashiH., NakanoK., ShigetaH.. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo.Biochem Biophys Res Commun1996; 226: 37–41.
145.
FrankeS., NiwaT., Deuther-ConradW.. Immunochemical detection of imidazolone in uremia and rheumatoid arthritis.Clin Chim Acta2000; 300: 29–41.
146.
LedererM.O., BuhlerH.P.. Cross-linking of proteins by Maillard processes-characterization and detection of a lysine-arginine cross-link derived from D-glucose.Bioorg Med Chem1999; 7: 1081–8.
147.
HofmannT., BorsW., StettmaierK.. Radical-assisted melanoidin formation during thermal processing of foods as well as under physiological conditions.J Agric Food Chem1999; 47: 391–6.
148.
PrabhakaramM., MossineV.V.. Characterization of a blue fluorophore isolated from in vitro reaction of N-proportional to-acetyllysine and 3-deoxyglucosone.Prep Biochem Biotechnol1998; 28: 319–38.
149.
NakamuraK., NakazawaY., lenagaK.. Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose.Biochem Biophys Res Commun1997; 232: 227–30.
150.
HayaseF., KoyamaT., KonishiY.. Novel dehydrofuroimidazole compounds formed by the advanced Maillard reaction of 3-deoxy-D-hexos-2-ulose and arginine residues in proteins.J Agric Food Chem1997; 45: 1137–42.
151.
FriedmanM.. Prevention of adverse effects of food browning.Adv Exp Med Biol1991; 289: 171–215.
152.
FriedmanM.. Food browning and its prevention: an overview.J Agric Food Chem1996; 44: 631–55.
153.
HenleT., SchwengerV., RitzE.. Preliminary studies on the renal handling of lactuloselysine from milk products.Czech J Food Sei2000; 18: S101–S102.
154.
CannellaG., MessaP.. Pathogenesis and treatment of secondary hyperparathyroidism in chronic renal disease.Int J Artif Organs1999; 22: 1–7.
155.
DruekeT.B.. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure.Kidney Int1995; 48: 259–72.
156.
PatelS.R., KeH.Q., VanholderR., KoenigR.J., HsuC.H.. Inhibition of calcitrlol receptor binding to vitamin D response elements by uremic toxins.J Clin Invest1995; 96: 50–9.
157.
BerdudI., Martin-MaloA., AlmadenY.. Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism.Nephrol Dial Transplant1996; 11: 1292–8.
158.
TorresA., LorenzoV., HernandezD.. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH.Kidney Int1995; 47: 1434–42.
159.
RostandS.G., DruekeT.B.. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.Kidney Int1999; 56: 383–92.
KotzmannH., KollerM., AbelaC.. Effects of parathyroid hormone and serum calcium on the phenotype and function of mononuclear cells in patients with primary hyperparathyroidism.Eur J Clin Invest1998; 28: 353–8.
162.
AlmadenY., CanalejoA., HernandezA.. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro.J Bone Miner Res1996; 11: 970–6.
163.
RodriguezM., FelsenfeldA.J., WilliamsC., PedersonJ.A., LlachF.. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients.J Am Soc Nephrol1991; 2: 1014–20.
164.
BlockG.A., Hulbert-ShearonT.E., LevinN.W., PortF.K.. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.Am J Kidney Dis1998; 31: 607–17.
165.
AmannK., GrossM.L., LondonG.M., RitzE.. Hyper-phosphataemia - a silent killer of patients with renal failure?Nephrol Dial Transplant1999; 14: 2085–7.
166.
LauA.H., KukJ.M., FransonK.L.. Phosphate-binding capacities of calcium and aluminum formulations.Int J Artif Organs1998; 21: 19–22.
167.
InoueH., KagoshimaM., KaibaraK.. Effects of anion exchange resin as phosphate binder on serum phosphate and iPTH levels in normal rats.Int J Artif Organs2000; 23: 243–9.
168.
MartinK.J., GonzalezE.A., GellensM.. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.J Am Soc Nephrol1998; 9: 1427–32.
169.
GoodmanW.G., FrazaoJ.M., GoodkinD.A.. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.Kidney Int2000; 58: 436–45.
170.
MiyataT., van Ypersele de StrihouC., KurokawaK., BaynesJ.W.. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications.Kidney Int1999; 55: 389–99.
171.
MiyataT., KurokawaK., van Ypersele de StrihouC.. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism.J Am Soc Nephrol2000; 11: 1744–52.
172.
OdaniH., ShinzatoT., MatsumotoY., UsamiJ., MaedaK.. Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction.Biochem Biophys Res Commun1999; 256: 89–93.
173.
Nilsson-ThorellC.B., MuscaluN., AndrenA.H., KjellstrandP.T., WieslanderA.P.. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes.Perit Dial Int1993; 13: 208–13.
174.
MiyataT., HorieK., UedaY.. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.Kidney Int2000; 58: 425–35.
175.
WieslanderA.P., NordinM.K., KjellstrandP.T., BobergU.C.. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.Kidney Int1991; 40: 77–9.
176.
WieslanderA.P., NordinM.K., MartinsonE., KjellstrandP.T., BobergU.C.. Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes.Clin Nephrol1993; 39: 343–8.
177.
WitowsklJ., KorybalskaK., WisniewskaJ.. Effect of glucose degradation products on human peritoneal mesothelial cell function.J Am Soc Nephrol2000; 11: 729–39.
178.
InagiR., MiyataT., YamamotoT.. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
Witko-SarsatV., FriedlanderM., Capeillere-BlandinC.. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int1996; 49: 1304–13.
181.
Witko-SarsatV., FriedlanderM., NguyenK.T.. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol1998; 161: 2524–32.
182.
MiyataT., MaedaK., KurokawaK., van Ypersele de StrihouC.. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure.Nephrol Dial Transplant1997; 12: 255–8.
183.
NiwaT., MiyazakiS., KatsuzakiT.. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis.Kidney Int1995; 48: 771–8.
184.
Capeillere-BlandinC., DelaveauT., Descamps-LatschaB.. Structural modifications of human beta 2 microglobulin treated with oxygen-derived radicals.Biochem J1991; 277: 175–82.
185.
MaggiE., BellazziR., FalaschiF.. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?Kidney Int1994; 45: 876–83.
186.
Nguyen-KhoaT., MassyZ.A., Witko-SarsatV.. Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: A novel pathway in atherogenesis?Biochem Biophys Res Commun1999; 263: 804–9.
187.
ViccaS., HennequinC., Nguyen-KhoaT.. Caspase-dependent apoptosis in THP-1 cells exposed to oxidized low- density lipoproteins.Biochem Biophys Res Commun2000; 273: 948–54.
188.
MarescauB., DeshmukhD.R., KockxM.. Guanidino compounds in serum, urine, liver, kidney, and brain of man and some ureotelic animals.Metabolism1992; 41: 526–32.
189.
MarescauB., NagelsG., PossemiersI.. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency.Metabolism1997; 46: 1024–31.
190.
De DeynP.P., MarescauB., D'HoogeR.. Guanidino compound levels in brain regions of non-dialyzed uremic patients.Neurochem Int1995; 27: 227–37.
191.
De DeynP.P., MarescauB., CuykensJ.J.. Guanidino compounds in serum and cerebrospinal fluid of nondialyzed patients with renal insufficiency.Clin Chim Acta1987; 167: 81–8.
192.
D'HoogeR., PeiY.Q., MarescauB., De DeynP.P.. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice.J Neuro Sci1992; 112: 96–105.
193.
D'HoogeR., PeiY.Q., ManilJ., De DeynP.P.. The uremic guanidino compound guanidinosuccinic acid induces behavioral convulsions and concomitant epileptiform electrocorticographic discharges in mice.Brain Res1992; 598: 316–20.
194.
De DeynP.P., MacdonaldR.L.. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture.Ann Neurol1990; 28: 627–33.
195.
D'HoogeR., De DeynP.P., Van de VijverG.. Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal cord neurones.Neurosci Lett1999; 265: 83–6.
196.
D'HoogeR., RaesA., LebrunP.. N-methyl-D-aspartate receptor activation by guanidinosuccinate but not by methylguanidine: behavioural and electrophysiological evidence.Neuropharmacology1996; 35: 433–40.
197.
D'HoogeR., PeiY.Q., De DeynP.P.. N-methyl-D-aspartate receptors contribute to guanidinosuccinate-induced convulsions in mice.Neurosci Lett1993; 157: 123–6.
198.
De DeynP.P., D'HoogeR., Van BogaertP.P., MarescauB.. Endogenous guanidino compounds as uremic neurotoxins.Kidney Int2001; 59(suppl 78): S77–83.
199.
De DeynP., MarescauB., LornoyW., BecausI., LowenthalA.. Guanidino compounds in uraemic dialysed patients.Clin Chim Acta1986; 157: 143–50.
200.
De DeynP., MarescauB., LornoyW.. Serum guanidino compound levels and the influence of a single hemodialysis in uremic patients undergoing maintenance hemodialysis.Nephron1987; 45: 291–5.
201.
MassyZ.A.. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end- products) for atherogenesis in uraemic patients.Nephrol Dial Transplant2000; 15 (suppl 5): S81–91.
202.
GuttormsenA.B., UelandP.M., SvarstadE., RefsumH.. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure.Kidney Int1997; 52: 495–502.
203.
RefsumH., HeilandS., UelandP.M.. Radioenzymic determination of homocysteine in plasma and urine.Clin Chem1985; 31: 624–8.
204.
van GuldenerC., DonkerA.J., JakobsC.. No net renal extraction of homocysteine in fasting humans.Kidney Int1998; 54: 166–9.
205.
van GuldenerC., KulikW., BergerR.. Homocysteine and methionine metabolism in ESRD: A stable isotope study.Kidney Int1999; 56: 1064–71.
206.
PernaA.F., CastaldoP., IngrossoD., De SantoN.G.. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.J Nephrol1999; 12: 230–40.
207.
MassyZ.A., CeballosI., Chadefaux-VekemensB.. Homocysteine, oxidative stress, and endothelium function in uremic patients.Kidney Int2001; 59: 243–5.
208.
van GuldenerC., JanssenM.J., LambertJ.. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.Nephrol Dial Transplant1998; 13: 106–12.
209.
ThambyrajahJ., LandrayM.J., McGlynnF.J.. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?Circulation2000; 102: 871–5.
210.
TouamM., ZingraffJ., JungersP.. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy.Kidney Int1999; 56: 2292–6.
211.
BostomA.G., SheminD., BagleyP.. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.Circulation2000; 101: 2829–32.
212.
YangoA., SheminD., HsuN.. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.Kidney Int2001; 59: 324–7.
213.
GulyassyP.F.. Can dialysis remove protein bound toxins that accumulate because of renal secretory failure?ASAIO J1994; 40: 92–4.
214.
NiwaT.. Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection.Clin Chem1993; 39: 108–11.
215.
ThompsonD.C., PereraK., FisherR., BrendelK.. Cresol isomers: comparison of toxic potency in rat liver slices.Toxicol Appl Pharmacol1994; 125: 51–8.
216.
GoodhartP.J., DeWolfW.E., KruseL.I.. Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol and related alkylphenols.Biochemistry1987; 26: 2576–83.
217.
LascellesP.T., TaylorW.H.. The effect upon tissue respiration in vitro of metabolites which accumulate in uraemic coma.Clin Sei1966; 31: 403–13.
218.
McNamaraP.J., LalkaD., GibaldiM.. Endogenous accumulation products and serum protein binding in uremia.J Lab Clin Med1981; 98: 730–40.
219.
YokoyamaM.T., TaboriC., MillerE.R., HogbergM.G.. The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites.Am J Clin Nutr1982; 35: 1417–24.
220.
HeipieperH.J., KewelohH., RehmH.J.. Influence of phenols on growth and membrane permeability of free and immobilized Escherichia coli.App Environ Microbiol1991; 57: 1213–17.
221.
VanholderR., De SmetR., WaterloosM.A.. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol.Kidney Int1995; 47: 510–7.
De KimpeJ., CornellsR., VanholderR.. In vitro methylation of arsenite by rabbit liver cytosol: effect of metal ions, metal chelating agents, methyltransferase inhibitors and uremic toxins.Drug Chem Toxicol1999; 22: 613–28.
224.
De SmetR., GlorieuxG., HsuC., VanholderR.. P-cresol and uric acid: two old uremic toxins revisited.Kidney Int1997; 62(suppl): S8–11.
225.
NiwaT., IseM., MiyazakiT., MeadaK.. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats.Nephron1993; 65: 82–7.
226.
De SmetR., VogeleereP., Van KaerJ., LameireN., VanholderR.. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/ protein binding in the serum of uremic patients.J Chromatogr A1999; 847: 141–53.
227.
TakamuraN., MaruyamaT., OtagiriM.. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.Clin Chem1997; 43: 2274–80.
228.
TsutsumiY., MaruyamaT., TakadateA., ShimadaH., OtagiriM.. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.Nephron2000; 85: 60–4.
229.
SatoM., KoyamaM., MiyazakiT., NiwaT.. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.Nephron1996; 74: 419–21.
230.
HendersonS.J., LindupW.E.. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia.J Pharmacol Exp Ther1992; 263: 54–60.
231.
CostiganM.G., LindupW.E.. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia.Kidney Int1996; 49: 634–8.
232.
MabuchiH., NakahashiH.. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum.Nephron1988; 49: 281–3.
233.
LimC.F., BernardB.F., de JongM.. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.J Clin Endocrinol Metab1993; 76: 318–24.
234.
NiwaT., AiuchiT., NakayaK.. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.Clin Nephrol1993; 39: 92–6.
235.
CostiganM.G., CallaghanC.A., LindupW.E.. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?Nephron1996; 73: 169–73.
236.
CostiganM.G., YaqoobM., LindupW.E.. Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant.Nephrol Dial Transplant1996; 11: 803–7.
237.
NiwaT., YazawaT., KodamaT.. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.Nephron1990; 56: 241–5.
238.
NiwaT.Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure.Semin Nephrol1996; 16: 167–82.
239.
NiwaT., AsadaH., tsutsuiS., MiyazakiT.. Efficient removal of albumin-bound furancarboxylic acid by protein- leaking hemodialysis.Am J Nephrol1995; 15: 463–7.
240.
VanholderR., Van LandschootN., De SmetR., SchootsA., RingoirS.. Drug protein binding in chronic renal failure: evaluation of nine drugs.Kidney Int1988; 33: 996–1004.
241.
DepnerT.A.. Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia.Kidney Int1981; 20: 511–8.
242.
NiwaT., IseM.. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.J Lab Clin Med1994; 124: 96–104.
243.
VanholderR.C., De SmetR.V., RingoirS.M.. Assessment of urea and other uremic markers for quantification of dialysis efficacy.Clin Chem1992; 38: 1429–36.
244.
NiwaT., TakedaN., TatematsuA., MaedaK.. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.Clin Chem1988; 34: 2264–7.
245.
MardiniH.A., HoenichN., BartlettK., RecordC.O.. Comparative value of different dialysis membranes, including a carbon coated membrane for removal of noxious substances in hepatic coma.Int J Artif Organs1979; 2: 290–5.
246.
KaziukaE.N., ChangT.M.. In-vitro assessment of the removal of phenols by ACAC hemoperfusion.Int J Artif Organs1979; 2: 215–21.
247.
JungersP., MassyZ.A., KhoaT.N.. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study.Nephrol Dial Transplant1997; 12: 2597–602.
248.
ParfreyP.S., HarnettJ.D.. Long-term cardiac morbidity and mortality during dialysis therapy.Adv Nephrol Necker Hosp1994; 23: 311–30.
249.
EckelR.H.. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases.N Engl J Med1989; 320: 1060–8.
250.
OlivecronaT., Bengtsson-OlivecronaG., OstergaardP.. New aspects on heparin and lipoprotein metabolism.Haemostasis1993; 23(suppl 1): S150–60.
AttmanP.O., SamuelssonO., AlaupovicP.. Diagnosis and classification of dyslipidemia in renal disease.Blood Purif1996; 14: 49–57.
259.
OiK., HiranoT., SakaiS., KawaguchiY., HosoyaT.. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.Kidney Int1999; 56(suppl 71): S227–8.
260.
FriedL., HutchisonA., StegmayrB., PrichardS., BargmanJ.M.. Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. ISPD guidelines/ recommendations. International Society for Peritoneal Dialysis.Perit Dial Int1999; 19: 7–16.
261.
Applebaum-BowdenD., HaffnerS.M., WahlP.W.. Postheparin plasma triglyceride lipases. Relationships with very low density lipoprotein triglyceride and high density lipoprotein 2 cholesterol.Arteriosclerosis1985; 5: 273–82.
262.
ChanM.K., PersaudJ., VargheseZ., MoorheadJ.F.. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients.Kidney Int1984; 25: 812–8.
263.
CarriereF., VergerR., LookeneA., OlivecronaG.. Lipase structures at the interface between chemistry and biochemistry.EXS1995; 73: 3–26.
264.
VaziriN.D., LiangK.. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure.Kidney Int1996; 50: 1928–35.
265.
CrawfordG.A., SavdieE., StewartJ.H., MahonyJ.F.. Inhibition of normal plasma lipases by serum from chronic renal failure patients.Trans Am Soc Artif Intern Organs1979; 25: 426–30.
266.
ArnadottirM., ThysellH., DallongevilleJ., FruchartJ.C., Nilsson-EhleP.. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure.Kidney Int1995; 48: 779–84.
267.
LookeneA., ChevreuilO., OstergaardP., OlivecronaG.. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization, and kinetics.Biochemistry1996; 35: 12155–63.
AlvestrandA., DeFronzoR.A., SmithD., WahrenJ.. Influence of hyperinsulinaemia on intracellular amino acid levels and amino acid exchange across splanchnic and leg tissues in uraemia.Clin Sei1988; 74: 155–63.
MuraseT., CattranD.C., RubensteinB., SteinerG.. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia.Metabolism1975; 24: 1279–86.
273.
CheungA.K., ParkerC.J., RenK., IveriusP.H.. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma.Kidney Int1996; 49: 1360–71.
274.
PetersonJ., OlivecronaT., Bengtsson-OlivecronaG.. Distribution of lipoprotein lipase and hepatic lipase between plasma and tissues: effect of hypertriglyceridemia.Biochim Biophys Acta1985; 837: 262–70.
ArnadottirM., Nilsson-EhleP.. Parathyroid hormone is not an inhibitor of lipoprotein lipase activity.Nephrol Dial Transplant1994; 9: 1586–9.
278.
PasternackA., VanttinenT., SolakiviT., KuusiT., KorteT.. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.Clin Nephrol1987; 27: 163–8.
279.
Aznar-SalattiJ., EscolarG., CasesA.. Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix.Nephrol Dial Transplant1995; 10: 2199–204.
280.
AreseM., StraslyM., RuvaC.. Regulation of nitric oxide synthesis in uraemia.Nephrol Dial Transplant1995; 10: 1386–97.
281.
HaaberA.B., EidemakI., JensenT., Feldt-RasmussenB., StrandgaardS.. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure.J Am Soc Nephrol1995; 5: 1581–4.
282.
GrisJ.C., BrangerB., VecinaF.. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients.Kidney Int1994; 46: 807–813.
283.
NakayamaM., YamadaK., YamamotoY.. Vascular endothelial dysfunction in patients on regular dialysis treatment.Clin Nephrol1994; 42: 117–20.
284.
JoannidesR., BakkaliE.H., Le RoyF.. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis.Nephrol Dial Transplant1997; 12: 2623–8.
PannierB., GuerinA.P., MarchaisS.J.. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease.Kidney Int2000; 57: 1091–9.
287.
VallanceP., LeoneA., CalverA., CollierJ., MoncadaS.. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet1992; 339: 572–5.
288.
BostomA.G., CulletonB.F.. Hyperhomocysteinemia in chronic renal disease.J Am Soc Nephrol1999; 10: 891–900.
289.
HofmannM.A., LallaE., LuY.. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.J Clin Invest2001; 107: 675–83.
290.
PrueferD., ScallaR., LeferA.M.. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide.Gen Pharmacol1999; 33: 487–98.
291.
KlinknerA.M., WaitesC.R., KernsW.D., BugelskiP.J.. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy.J Histochem Cytochem1995; 43: 1071–8.
292.
DimmeierS., HaendelerJ., GalleJ., ZeiherA.M.. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury’ hypothesis.Circulation1997; 95: 1760–3.
293.
MurugesanG., ChisolmG.M., FoxP.L.. Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro.J Cell Biol1993; 120: 1011–9.
294.
BoissonneaultG.A., WangY., ChungB.H.. Oxidized low-density lipoproteins delay endothelial wound healing: lack of effect of vitamin E.Ann Nutr Metab1995; 39: 1–8.
295.
IshiiH., KizakiK., HorieS., KazamaM.. Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes.J Biol Chem1996; 271: 8458–65.
296.
LevinRl, KantoffP.W., JaffeE.A.. Uremic levels of oxalic acid suppress replication and migration of human endothelial cells.Arteriosclerosis1990; 10: 198–207.
297.
SchmidtA.M., HoriO., ChenJ.X.. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM- 1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.J Clin Invest1995; 96: 1395–403.
298.
EspositoC., GerlachH., BrettJ., SternD., VlassaraH.. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.J Exp Med1989; 170: 1387–407.
DouL., CeriniC., BrunetP., GuilianelliC., GrauG., SampolJ., De SmetR., VanholderR., BerlandY.. Para-cresol decreases endothelial cell response to cytokine stimulation (Abstract).J Am Soc Nephrol2000; 11, 59A.
301.
ZimmermannJ., HerrlingerS., PruyA., MetzgerT., WannerC.. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.Kidney Int1999; 55: 648–58.
302.
KimmelP.L., PhillipsT.M., SimmensS.J.. Immunologic function and survival in hemodialysis patients.Kidney Int1998; 54: 236–44.
303.
BologaR.M., LevineD.M., ParkerT.S.. lnterleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.Am J Kidney Dis1998; 32: 107–14.
304.
StenvinkelP., LindholmB., HeimburgerM., HeimburgerO.. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease.Nephrol Dial Transplant2000; 15: 1624–30.
305.
StenvinkelP.. Inflammatory and atherosclerotic interactions in the depleted uremic patient.Blood Purif.2001; 19: 53–61.
306.
Descamps-LatschaB., HerbelinA., NguyenA.T.. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.J Immunol1995; 154: 882–92.
307.
MemoliB., PostiglioneL., CianciarusoB.. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients.Kidney Int2000; 58: 417–24.
308.
PooleS., BirdT.A., SelkirkS.. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney.Cytokine1990; 2: 416–22.
309.
Riemsdijk-van OverbeekeI.C., BaanC.C., HesseC.J.. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure.Clin Nephrol2000; 53: 115–23.
310.
EspinozaM., AguileraA., AuxiliadoraB.M.. Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients.Adv Perit Dial1999; 15: 82–6.
311.
BergstromJ., FurstP., ZimmermanL.. Separation, isolation, and identification of middle molecules.Artif Organs1981; 4 Suppl: 5–7.
312.
WieslanderA., LindenT., MusiB.. Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids.Contrib Nephrol2001; 82–9.
313.
MiyataT., KurokawaK.. Carbonyl stress: increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia.Int J Artif Organs1999; 22: 195–8.
314.
DeppischR.M., BeckW., GoehlH., RitzE.. Complement components as uremic toxins and their potential role as mediators of microinflammation.Kidney Int2001; 59(suppl 78): S271–77.
315.
SchroderM., RiedelE., BeckW., DeppischR.M., PommerW.. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.Kidney Int2001; 59(suppl 78): S19–24.
316.
UrsinoM., ColiL., BrighentiC.. Mathematical modeling of solute kinetics and body fluid changes during profiled hemodialysis.Int J Artif Organs1999; 22: 94–107.
VidiE., BiancoF., PanzettaG.. The contribution of hemofiltration among the treatment modalities of chronic uremia.Int J Artif Organs1993; 16: 809–15.
319.
RoncoC., BrendolanA., CrepaldiC.. Technical and clinical evaluation of a new asymmetric polysulfone membrane (Biosulfane).Int J Artif Organs1993; 16: 573–84.
320.
WinchesterJ.F., RoncoC., BradyJ.A.. Sorbent augmented dialysis: minor addition or major advance in therapy?Blood Purif2001; 19: 255–9.
321.
BotellaJ., GhezziP.M., Sanz-MorenoC.. Adsorption in hemodialysis.Kidney Int2000; 58(suppl 76): S60–5.
322.
La GrecaG., BrendolanA., GhezziP.M.. The concept of sorbent in hemodialysis.Int J Artif Organs1998; 21: 303–8.
323.
GurlandH.J., FernandezJ.C., SamtlebenW., CastroL.A.. Sorbent membranes used in a conventional dialyzer format. In vitro and clinical evaluation.Artif Organs1978; 2: 372–4.
324.
SteczkoJ., BaxK.C., AshS.R.. Effect of hemodiabsorption and sorbent-based pheresis on amino acid levels in hepatic failure.Int J Artif Organs2000; 23: 375–88.
StangeJ., MitznerS.. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver.Int J Artif Organs1996; 19: 677–91.
327.
Marinez de FranciscoA.L., GhezziP.M., BrendolanA.. Hemodiafiltration with online regeneration of the ultrafiltrate.Kidney Int2000; 58(suppl 76): S66–71.
328.
de FranciscoA.L., PineraC., HerasM.. Hemodiafiltration with on-line endogenous reinfusion.Blood Purif2000; 18: 231–6.
329.
FalkenhagenD., StroblW., VogtG.. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances.Artif Organs1999; 23: 81–6.
330.
TettaC., CavaillonJ.M., SchulzeM.. Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption.Nephrol Dial Transplant1998; 13: 1458–64.
331.
GejyoF., HommaN., HasegawaS., ArakawaM.. A new therapeutic approach to dialysis amyloidosis: intensive removal of beta 2-microglobulin with adsorbent column.Artif Organs1993; 17: 240–3.
332.
NakazawaR., AzumaN., SuzukiM.. A new treatment for dialysis-related amyloidosis with beta 2- microglobulin adsorbent column.Int J Artif Organs1993; 16: 823–9.
333.
RoncoC., GhezziP.M., MorrisA.. Blood flow distribution in sorbent beds: analysis of a new sorbent device for hemoperfusion.Int J Artif Organs2000; 23: 125–30.
334.
RoncoC., BrendolanA., WinchesterJ.F.. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta(2)-microglobulin in hemodialysis.Blood Purif2001; 19: 260–3.
335.
KleinE.. Affinity membranes: a 10-year review.J Membr Sci2001; 178: 1–27.
